Dermatology, 2018 – Newsletter #3
New ETAP-Lab studies on TEMISIS’ drug candidate TEM1657 for Psoriasis
ETAP-Lab performed new studies for the account of TEMISIS on a mouse imiquimod-induced psoriasis model. The output of these studies showed that TEM1657 brings remarkable effects on psoriasis:
- Higher efficacy compared to the reference molecule
- No side effects
- Oral administration, which is new for the psoriasis treatment
The French biotech company “Temesis”, subsidiary of Plant Advanced Technologies, recently published a new press release to announce these new promising preclinical results on psoriasis with TEM1657.
The results of these new ETAP-Lab studies, together with in vitro studies, have been presented by TEMISIS in a poster at the International Investigative Dermatology 2018 in Orlando (Florida, U.S.A.) last May.
The mechanism of action of TEM1657 uses the Th17-dependant pathway which does not only give hope to psoriasis treatment but also to widespread inflammatory conditions such as Crohn’s disease or ulcerative colitis.
Figure 1: In vitro efficacy profile: microscopic view of the cells
Figure 2: In vivo efficacy profile: PASI scoring
Figure 3: In vivo efficacy profile: Skin shape and histology
ETAP-Lab has strong experience in the field of dermatology research by developing a wide portfolio of original in vivo models.
With total transparency, our expertise and know-how include:
– Respecting chronobiology and animal well-being
– Considering chronopharmacology during treatments
– Evaluating animal behavior to confirm beneficial/ adverse effects of treatments